troglitazone has been researched along with Osteosarcoma in 3 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteosarcoma often develops micrometastases in the lung prior to diagnosis, causing a fatal outcome." | 5.36 | Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8. ( Aizawa, J; Kamei, S; Kidani, T; Masuno, H; Norimatsu, Y; Sakayama, K; Yamamoto, H, 2010) |
| " In our study, we investigated whether treatment with troglitazone (TRO), a known PPAR gamma agonist, induced apoptosis in the human osteosarcoma (OS) cell lines G292, MG63, SAOS and U2OS that express PPAR gamma." | 3.71 | Troglitazione affects survival of human osteosarcoma cells. ( Alessandra Gobbi, G; Lattanzi, G; Lucarelli, E; Maini, V; Marmiroli, S; Mordenti, M; Picci, P; Reggiani, M; Sangiorgi, L; Scrimieri, F; Zambon Bertoja, A, 2002) |
| "Four osteosarcoma cell lines (143B, MNNG/HOS, MG-63, and TE-85) were treated with proliferator-activated receptor (PPAR)gamma agonists, troglitazone and ciglitazone, and a retinoid X receptor (RXR) ligand, 9-cis retinoic acid." | 3.71 | Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. ( Breyer, B; Cheng, H; Feng, T; Haydon, RC; He, TC; Ishikawa, A; Jiang, W; Montag, A; Peabody, T; Simon, MA; Zhou, L, 2002) |
| "Osteosarcoma often develops micrometastases in the lung prior to diagnosis, causing a fatal outcome." | 1.36 | Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8. ( Aizawa, J; Kamei, S; Kidani, T; Masuno, H; Norimatsu, Y; Sakayama, K; Yamamoto, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aizawa, J | 1 |
| Sakayama, K | 1 |
| Kamei, S | 1 |
| Kidani, T | 1 |
| Yamamoto, H | 1 |
| Norimatsu, Y | 1 |
| Masuno, H | 1 |
| Lucarelli, E | 1 |
| Sangiorgi, L | 1 |
| Maini, V | 1 |
| Lattanzi, G | 1 |
| Marmiroli, S | 1 |
| Reggiani, M | 1 |
| Mordenti, M | 1 |
| Alessandra Gobbi, G | 1 |
| Scrimieri, F | 1 |
| Zambon Bertoja, A | 1 |
| Picci, P | 1 |
| Haydon, RC | 1 |
| Zhou, L | 1 |
| Feng, T | 1 |
| Breyer, B | 1 |
| Cheng, H | 1 |
| Jiang, W | 1 |
| Ishikawa, A | 1 |
| Peabody, T | 1 |
| Montag, A | 1 |
| Simon, MA | 1 |
| He, TC | 1 |
3 other studies available for troglitazone and Osteosarcoma
| Article | Year |
|---|---|
Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8.
Topics: Animals; Antigens, CD34; Cell Line, Tumor; Chromans; Humans; Hypoglycemic Agents; Lung Neoplasms; Ma | 2010 |
Troglitazione affects survival of human osteosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Count; Cell Division; Cell | 2002 |
Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma.
Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Division; Chromans; Dose- | 2002 |